Yuan Xu - 04 Jan 2022 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Director
Signature
/s/ Chris Frankenfield , Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
04 Jan 2022
Transactions value $
$0
Form type
4
Filing time
06 Jan 2022, 17:48:24
Previous filing
05 Aug 2021
Next filing
03 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +26.4K $0.00 26.4K 04 Jan 2022 Common Stock 26.4K $15.92 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was granted on January 4, 2022 and will vest in three equal installments on January 4, 2023, January 4, 2024 and January 4, 2025.